When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Lisaftoclax - Wikipedia

   en.wikipedia.org/wiki/Lisaftoclax

   Lisaftoclax is an investigational new drug being developed by Ascentage Pharma for the treatment of hematological malignancies, particularly chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

3. Duvelisib - Wikipedia

   en.wikipedia.org/wiki/Duvelisib

   In April 2018, Verastem filed a New Drug Application (NDA) for duvelisib for the treatment of relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and accelerated approval for relapsed or refractory follicular lymphoma (FL). The FDA approved the application in September 2018.

4. Zanubrutinib - Wikipedia

   en.wikipedia.org/wiki/Zanubrutinib

   It is also indicated for the treatment of adults with relapsed or refractory marginal zone lymphoma who have received at least one anti-CD20-based regimen. [12] In January 2023, the US Food and Drug Administration (FDA) approved zanubrutinib for chronic lymphocytic leukemia or small lymphocytic lymphoma. [19]

5. What's Going On With Eli Lilly Stock On Tuesday? - AOL

   www.aol.com/finance/whats-going-eli-lilly-stock...

   On Monday, Eli Lilly And Co (NYSE:LLY) announced results from the Phase 3 BRUIN CLL-321 trial evaluating pirtobrutinib in adult patients with chronic lymphocytic leukemia or small lymphocytic ...

6. Phosphoinositide 3-kinase inhibitor - Wikipedia

   en.wikipedia.org/wiki/Phosphoinositide_3-kinase...

   Idelalisib (trade name Zydelig; codenamed CAL-101, GS-1101; PIK3CD inhibitor): FDA-approved in July 2014 for treatment of three types of blood cancers: treatment of relapsed or refractory chronic lymphocytic leukemia (CLL) in combination with rituximab, treatment of relapsed small lymphocytic lymphoma after at least two prior systemic therapies, and treatment of follicular lymphoma (FL) after ...

7. Acalabrutinib - Wikipedia

   en.wikipedia.org/wiki/Acalabrutinib

   Acalabrutinib, sold under the brand name Calquence, is a medication used to treat various types of non-Hodgkin lymphoma, including mantle cell lymphoma (MCL) and chronic lymphocytic leukemia/small lymphocytic Lymphoma (CLL/SLL). [7] It may be used both in relapsed as well as in treatment-naive settings. [8]